B1 cont.

5. (Amended) An adenoviral vector as claimed in [one of claims 2 to 4] claim 2, which is derived, in addition, from the genome of an adenovirus by deletion of all or part of the E4 region.

B2

8. (Amended) An adenoviral vector as claimed in claim 6 [or 7], which is derived, in addition, from the genome of an adenovirus by deletion of all or part of the E1B region.

9. (Amended) An adenoviral vector as claimed in [one of claims 6 to 8] claim 6, which is derived, in addition, from the genome of an adenovirus by deletion of all or part of the E3 region.

10. (Amended) An adenoviral vector as claimed in claim 6[, 8 or 9], which is derived, in addition, from the genome of an adenovirus by deletion of all or part of the E4 region.

11. (Amended) An adenoviral vector as claimed in [one of claims 3 to 5, 9 or 10] claim 3, which is derived from the genome of an adenovirus by partial deletion of the E3 region of said genome, while maintaining the portion of said E3 region coding for the gp19kDa protein.

B3

13. (Amended) An adenoviral vector as claimed in [one of claims 1 to 12] claim 1, which is derived from the genome of an adenovirus by deletion of all or part of the E1A region and a portion of the encapsidation region.

B4

15. (Amended) An adenoviral vector as claimed in [one of claims 1 to 14] claim 1, which is derived from the genome of an adenovirus selected from canine, avian and human adenoviruses.

B5

18. (Amended) An adenoviral vector as claimed in claim 16 [or 17], which is derived from the genome of a human adenovirus type 5, in particular by deletion of the portion of the E3 region extending from nucleotide 27871 to nucleotide 30748.

19. (Amended) An adenoviral vector as claimed in [one of claims 16 to 18] claim 16, which is derived from the genome of a human adenovirus type 5 by deletion of the portion of the E4 region extending from nucleotide 32800 to nucleotide 35826.

20. (Amended) An adenoviral vector as claimed in [one of claims 1 to 19] claim 1, which is derived from the genome of an adenovirus by deletion of at least 18% of the genome of said virus.

B6

26. (Amended) An adenoviral vector as claimed in [one of claims 1 to 25] claim 1, which comprises, in addition, an exogenous nucleotide sequence.

B7

28. (Amended) An adenoviral vector as claimed in [either of claims 26 or 27] claim 26, which comprises, in addition, a gene coding for a protein which trans-activates non-adenoviral transcription; said gene being placed under the control of the elements needed for the expression of said protein in a host cell.

B8

30. (Amended) An adenovirus particle comprising an adenoviral vector as claimed in [one of claims 1 to 29] claim 1.

31. (Amended) A eukaryotic host cell comprising an adenoviral vector as claimed on [one of claims 1 to 29] claim 1 [or an adenovirus particle as claimed in claim 30].

B9

36. (Amended) A complementation line as claimed in [one of claims 33 to 35] claim 33, comprising, in particular, all or part of the E1A region and the whole of the E1B region of the genome of an adenovirus coding for the early proteins.

37. (Amended) A complementation line as claimed in [one of claims 32 to 36] claim 32, comprising, in particular, a portion of the genome of an adenovirus selected from canine, avian and human adenoviruses.

B10

40. (Amended) A complementation line as claimed in claim 38 [or 39], comprising, in particular, the portion of the E4 region of the genome of a human adenovirus type 5 extending from nucleotide 32800 to nucleotide 35826.

B11

42. (Amended) A complementation line as claimed in [one or claims 32 to 41] claim 32, comprising a portion of E1A region of the genome of an adenovirus lacking its natural promoter; said portion being placed under the control of a suitable promoter.

B12

45. (Amended) A complementation line as claimed in claim 43 [or 44], in which said portion of the E1A region is placed under the control of a promoter which is inducible by the *Saccharomyces cerevisiae* Ga14 protein which trans-activates transcription.

46. (Amended) A complementation line as claimed in [one of claims 32 to 45] claim 32, comprising, in addition, a gene coding for a selectable marker.

B13

48. (Amended) A complementation line as claimed in claim 46 [or 47], in which the selectable gene is placed under the control of a promoter which is inducible by a protein which trans-activates transcription encoded by the E1A region of the genome of a wild-type adenovirus, in particular under the control of the promoter of the E2 region of said genome.

B13 cont.

49. (Amended) A complementation line as claimed in [one of claims 32 to 48] claim 32, derived from a cell line which is acceptable from a pharmaceutical standpoint.

B14

51. (Amended) A complementation line as claimed in [one of claims 32 to 48] claim 32, derived from a human embryo retinal cell.

B15

53. (Amended) A method as claimed in claim 52, according to which a complementation line [as claimed in one of claims 32 to 51] is employed.

54. (Amended) A therapeutic or prophylactic use of an adenoviral vector as claimed in [one of claims 1 to 29,] claim 1 [an adenovirus particle as claimed in claim 30 or obtained employing a method as claimed in claim 52 or 53, a eukaryotic host cell as claimed in claim 31 or a complementation line as claimed in one of claims 32 to 51].

55. (Amended) A pharmaceutical composition comprising as therapeutic or prophylactic agent an adenoviral vector as claimed in [one of claims 1 to 29] claim 1, [an adenovirus particle as claimed in claim 30 or obtained employing a method as claimed in claim 52 or 53, a eukaryotic cell as claimed in claim 31 or a complementation line as claimed in one of claims 32 to 51,] in combination with a vehicle which is acceptable from a pharmaceutical standpoint.

Please add the following new claims:

B16
R.663

--56. A recombinant adenovirus comprising an adenovirus genome having a foreign gene and a promoter for expressing said foreign gene, wherein the function of an E2A gene is completely deleted by removing a part or all of said E2A gene.